Literature DB >> 25898965

MET-Mutated NSCLC with Major Response to Crizotinib.

Melody A Mendenhall1, Jonathan W Goldman2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25898965     DOI： 10.1097/JTO.0000000000000491

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  13 in total

1.  MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval.

Authors:  Thanyanan Reungwetwattana; Sai-Hong Ignatius Ou
Journal:  Transl Lung Cancer Res       Date:  2015-12

Review 2.  MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.

Authors:  Sara Pilotto; Anastasios Gkountakos; Luisa Carbognin; Aldo Scarpa; Giampaolo Tortora; Emilio Bria
Journal:  Ann Transl Med       Date:  2017-01

3.  Has MET met its match?

Authors:  Alain Borczuk; Daniel Paucar; Balazs Halmos
Journal:  Ann Transl Med       Date:  2016-03

4.  Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.

Authors:  Mark M Awad; Giulia C Leonardi; Sasha Kravets; Suzanne E Dahlberg; Alexander Drilon; Sinead A Noonan; D Ross Camidge; Sai-Hong I Ou; Daniel B Costa; Shirish M Gadgeel; Conor E Steuer; Patrick M Forde; Viola W Zhu; Yoko Fukuda; Jeffrey W Clark; Pasi A Jänne; Tony Mok; Lynette M Sholl; Rebecca S Heist
Journal:  Lung Cancer       Date:  2019-05-11       Impact factor: 5.705

5.  Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer.

Authors:  Edward B Garon; Paige Brodrick
Journal:  Drugs       Date:  2021-02-27       Impact factor: 9.546

Review 6.  The multiple paths towards MET receptor addiction in cancer.

Authors:  Leslie Duplaquet; Zoulika Kherrouche; Simon Baldacci; Philippe Jamme; Alexis B Cortot; Marie-Christine Copin; David Tulasne
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

7.  MET Exon 14 Skipping in Non-Small Cell Lung Cancer.

Authors:  Rebecca S Heist; Hyo Sup Shim; Shalini Gingipally; Mari Mino-Kenudson; Long Le; Justin F Gainor; Zongli Zheng; Martin Aryee; Junfeng Xia; Peilin Jia; Hailing Jin; Zhongming Zhao; William Pao; Jeffrey A Engelman; A John Iafrate
Journal:  Oncologist       Date:  2016-03-28

Review 8.  A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations.

Authors:  Mariacarmela Santarpia; Marco Massafra; Vittorio Gebbia; Antonio D'Aquino; Claudia Garipoli; Giuseppe Altavilla; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2021-03

9.  MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer.

Authors:  Difan Zheng; Rui Wang; Ting Ye; Su Yu; Haichuan Hu; Xuxia Shen; Yuan Li; Hongbin Ji; Yihua Sun; Haiquan Chen
Journal:  Oncotarget       Date:  2016-07-05

Review 10.  [MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].

Authors:  Limei Yin; You Lu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.